• Alias: HuLuc63; BMS-901608; PDL-063
    • Humanized monoclonal Ig G1 immunostimulatory mAb directed against signaling lymphocytic activation molecule family member 7 (SLAMF7, also called CS1 [cell surface glycoprotein CD2 subset 1])
    • Treatment of relapsed/refractory MM (in combination with lenalidomide and dexamethasone) in patients who have received one to three prior therapies
    • Recommended dose: Cycles 1 and 2: 10 mg/kg IV weekly on days 1, 8, 15, and 22 and then in cycle 3 and beyond: 10 mg/kg IV every 2 weeks on days 1 and 15. Both in combination with lenalidomide and dexamethasone. ns with acetaminophen, IV, or PO diphenhydramine and IV or PO H1 antagonist
    Other topics in Targeted and Immunotherapy Agents